Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 Heel Prick Test: Importance and impact on newborn health Teste do Pezinho: Importância e impacto na saúde do recém-nascido Prueba del Talón: Importancia e impacto en la salud del recién nacido Received: 09/14/2026 | Accepted: 09/20/2026 | Published: 09/21/2026 Nathália Neves Gonçalves ORCID: https://orcid.org/0009-0007-0314-536X Universidade Franciscana, Brazil E-mail: nathalianeves3234@gmail.com Taíse Regina Schuster Montagner ORCID: https://orcid.org/0009-0004-1985-2243 Universidade Franciscana, Brazil E-mail: taise.schuster@ufn.edu.br Diulie Valente de Souza ORCID: https://orcid.org/0009-0004-8453-9210 Universidade Franciscana, Brazil E-mail: diulie.valente@ufn.edu.br Abstract This article aims to identify flaws in the dissemination of information and the factors that hinder its performance, with the purpose of promoting awareness about newborn screening and, consequently, suggesting strategies to improve the dissemination of correct information and expand the proper performance of this vital intervention instrument. Newborn Screening, known in Brazil as the “Heel Prick Test,” is essential for the early detection of metabolic, genetic, enzymatic, and endocrine diseases in newborns, enabling interventions that prevent irreversible sequelae and reduce infant mortality. This study presents a narrative literature review, with emphasis on the evolution of the National Newborn Screening Program (PNTN), which initially covered six diseases and was expanded by Law No. 14,154/2021 to include up to 50 diseases distributed across 14 groups. The results indicate that, despite the expansion of the National Newborn Screening Program (PNTN) through Law No. 14,154/2021, structural, logistical, and professional-training challenges persist. The study concludes that public investments and educational strategies aimed at the population and health professionals are necessary to ensure equity and accessibility of Newborn Screening throughout the country. Keywords: Neonatal screening; Heel Prick Test; Public Health; Early diagnosis; Newborn. Resumo Este artigo tem como objetivo identificar falhas na disseminação de informações e os fatores que dificultam sua realização, com o propósito de promover a conscientização sobre a triagem neonatal e, consequentemente, sugerir estratégias para melhorar a disseminação de informações corretas e ampliar a adequada realização deste instrumento vital de intervenção. A Triagem Neonatal, conhecida no Brasil como “Teste do Pezinho”, é essencial para a detecção precoce de doenças metabólicas, genéticas, enzimáticas e endócrinas em recém-nascidos, possibilitando intervenções que previnem sequelas irreversíveis e reduz a mortalidade infantil. Este estudo apresenta uma revisão narrativa de literatura, com ênfase na evolução do Programa Nacional de Triagem Neonatal (PNTN), que inicialmente abrangia seis doenças e foi ampliado pela Lei nº 14.154/2021 para abranger até 50 doenças distribuídas em 14 grupos. Os resultados apontam que, apesar da expansão do Programa Nacional de Triagem Neonatal (PNTN) pela Lei nº 14.154/2021, persistem dificuldades estruturais, logísticas e de formação profissional. O estudo conclui que são necessários investimentos públicos e de estratégias educativas voltadas à população e aos profissionais de saúde, para garantir a equidade e facilidade da Triagem Neonatal em todo o país. Palavras-chave: Triagem neonatal; Teste do Pezinho; Saúde Pública; Diagnóstico precoce; Recém-nascido. Resumen Este artículo tiene como objetivo identificar fallas en la difusión de información y los factores que dificultan su realización, con el propósito de promover la concienciación sobre el cribado neonatal y, en consecuencia, sugerir estrategias para mejorar la difusión de información correcta y ampliar la adecuada realización de este instrumento vital de intervención. El cribado neonatal, conocido en Brasil como “Prueba del Talón”, es esencial para la detección precoz de enfermedades metabólicas, genéticas, enzimáticas y endocrinas en recién nacidos, permitiendo intervenciones que previenen secuelas irreversibles y reducen la mortalidad infantil. Este estudio presenta una revisión narrativa de la literatura, con énfasis en la evolución del Programa Nacional de Cribado Neonatal (PNTN), que inicialmente abarcaba 1 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 seis enfermedades y fue ampliado por la Ley nº 14.154/2021 para incluir hasta 50 enfermedades distribuidas en 14 grupos. Los resultados indican que, a pesar de la ampliación del PNTN, persisten dificultades estructurales, logísticas y de formación profesional. El estudio concluye que son necesarias inversiones públicas y estrategias educativas dirigidas a la población y a los profesionales de salud para garantizar la equidad y el acceso al cribado neonatal en todo el país. Palabras clave: Cribado neonatal; Prueba del Talón; Salud Pública; Diagnóstico precoz; Recién nacido. 1. Introduction Healthcare access from birth is a right of every citizen, and in this context, the Newborn Screening test (NST) emerges as one of the most important strategies to guarantee this prerogative. This public health tool is responsible for the early diagnosis of various metabolic, genetic, enzymatic, and endocrine diseases in newborns which, if not identified and treated in a timely manner, can severely impair child development, causing irreversible sequelae or even death (Brasil, 2016). Performing the NST consists of collecting a few drops of blood from the baby's heel, ideally carried out between the 2nd and 5th day of the child's life, although it can be extended for a maximum of 30 days to avoid late initiation of treatment. This methodology allows for the detection of asymptomatic conditions in their early phase, enabling early therapeutic intervention that significantly improves the newborn's quality of life (Wyzykowski, 2022). Historically, the NST was developed by Robert Guthrie in the United States in 1961, initially to detect phenylketonuria. In Brazil, it was included in the National Newborn Screening Program (PNTN) and became mandatory throughout the national territory starting in 2001, initially screening for six diseases, such as phenylketonuria, congenital hypothyroidism, sickle cell disease, cystic fibrosis, congenital adrenal hyperplasia, and biotinidase deficiency (Bhattacharya et al., 2021). With the advancement of public policies and scientific development, Law No. 14.154 was approved in May 2021 to expand the test in Brazil, where it would come to detect up to 50 diseases distributed across 14 distinct groups. The implementation of the expansion was planned to occur gradually, divided into five stages: the first stage provided for the inclusion of diseases associated with excess phenylalanine, congenital toxoplasmosis, and hemoglobinopathies. In the second expansion stage, it is possible to detect urea cycle disorders, high blood galactose levels, amino acidopathies, and fatty acid betaoxidation disorders. In the third stage, diseases affecting cellular functioning will be offered, and in the fourth stage, genetic problems of the immune system. In the fifth and final stage of implementing the expanded NST available through the SUS, the exam also aims to include the spinal muscular atrophy test (Brasil, 2022). Despite this, the complete implementation of the expanded Newborn Screening test still faces challenges and varies among different Brazilian states (Souza et al., 2025). Factors such as the infrastructure of collection points, adequate training of healthcare professionals, the guarantee of sufficient financial resources, and barriers in disseminating information about the test and its access can compromise the effectiveness of the screening (Brasil, 2022). Newborn screening coverage, although higher than non-screened individuals between 2016 and 2020, still presents a percentage of collections performed within the recommended timeframe (up to the 5th day of life) that decreased in some periods, indicating the need for improvements in adherence to it (Brasil, 2025). The repercussions of late diagnosis of diseases detectable by newborn screening go beyond the scope of care, reflecting significant economic and social impacts. Children not identified early present a higher risk of developing permanent sequelae, demanding complex treatments and hospitalizations, which reinforces the need for public policies that must consider broad and long-term analyses, including the social and familial costs resulting from late diagnosis (Grosse et al., 2016). Considering its importance for public health and the challenges inherent to its full implementation, this study seeks to highlight the impact of the Newborn Screening test on newborn health and the changes resulting from its expansion (Brasil, 2024). Furthermore, it aims to identify flaws in the dissemination of information and the factors that hinder its performance, with the purpose of promoting awareness about newborn screening and, consequently, suggesting strategies to improve the 2 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 dissemination of correct information and expand the proper performance of this vital intervention instrument. A descriptive study (Risemberg et al., 2026a) was conducted using a qualitative approach (Risemberg et al., 2026b; Pereira et al., 2018) and taking the form of a narrative literature review (Ogassawara et al., 2025; Fernandes, Vieira & Castelhano, 2023). The methodology of this study was divided into stages as shown in Figure 1. 2. Methodology A descriptive study (Risemberg et al., 2026a) was conducted using a qualitative approach (Risemberg et al., 2026b; Pereira et al., 2018) and taking the form of a narrative literature review (Ogassawara et al., 2025; Fernandes, Vieira & Castelhano, 2023). The methodology of this study was divided into stages as shown in Figure 1. Figure 1 – Flowchart of the methodology of the narrative review on Newborn Screening (Newborn Screening Test). Source: Authors' own elaboration (2025). 3 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 3. Results and Discussion 3.1 Newborn Screening Test: importance, detected conditions, and advancements of the expanded panel The Newborn Screening Test (NST) was developed by Professor Robert Guthrie, an American medical microbiologist, in 1961 in the United States. The technique consists of a laboratory exam performed using blood collected from the newborn's heel. This exam was considered innovative at the time and allowed for the detection of hyperphenylalaninemias, disorders related to the accumulation of phenylalanine in the blood, such as phenylketonuria, a severe metabolic disease that can cause intellectual disability if untreated (Bhattacharya et al., 2021). In Brazil, the NST was included in the National Newborn Screening Program (PNTN), becoming mandatory throughout the national territory since 2001 through Ordinance No. 822 (Brasil, 2001). The objective of the PNTN is to early detect genetic, congenital, and infectious conditions, even before symptoms manifest, enabling the immediate start of effective treatments. Currently, the NST offered by the SUS (Unified Health System) allows the screening of six diseases, which are: Phenylketonuria (PKU), Congenital Hypothyroidism (CH), Sickle Cell Disease (SCD), Hemoglobinopathies, and Cystic Fibrosis (CF). The detection of Congenital Adrenal Hyperplasia (CAH) and Biotinidase Deficiency (BD) were included in 2012 by GM/MS Ordinance No. 2.829 (Brasil, 2021). Most of the diseases detected by the NST are related to inborn errors of metabolism (IEMs), a set of genetic conditions, mostly transmitted in an autosomal recessive manner, that cause the total or partial block of a specific metabolic pathway, usually due to an enzyme deficiency. This block compromises the processing and proper utilization of macronutrients, such as carbohydrates, proteins, and lipids, resulting in the accumulation of substrates, deficiency of the final product, or activation of alternative metabolic pathways—factors that directly influence the clinical manifestation and severity of the disease (Cossu et al., 2023; Jeanmonod et al., 2025). IEMs can be classified into two main categories: Category 1 includes problems in only one functional system, an anatomical system, or organ where clinical signs are regular, which aids in diagnosis. Category 2 can have an effect on a common metabolic pathway. They are associated with a group of disorders with a broad heterogeneity of diseases that largely affect children and newborns, causing sequelae and mortality in affected patients (Santos, 2024). Although inborn errors of metabolism are individually considered rare diseases, together they represent an important group of genetic conditions that demand high clinical suspicion and adequate diagnostic investigation when suggestive signs and symptoms are present (Kern et al., 2023; Rahman et al., 2024). Furthermore, advancements in metabolic medicine, molecular biology, and diagnostic technologies have significantly expanded therapeutic possibilities and improved the early identification of these conditions, especially through the expansion and modernization of Newborn Screening Programs (Tang et al., 2024). The NST, as part of newborn screening, is an essential tool for detecting various conditions that, if not identified and treated in time, can cause severe and even fatal sequelae. Among the screened diseases, Sickle Cell Disease stands out—an autosomal recessive genetic condition that causes modifications in the synthesis or structure of hemoglobin. The disease occurs due to a mutation on chromosome 11, which promotes the substitution of the amino acid glutamic acid by valine at position 6 of the N-terminal end of the β-globin chain. This alteration leads to the production of hemoglobin S (HbS), present in all erythrocytes of affected individuals (Wyzykowski, 2022). Sickle cells undergo membrane changes as they are rigid, rupture, and can lead to intravascular hemolysis and chronic hemolytic anemia. Children suffering from this disease present with hemolytic anemia, vaso-occlusive crises, pain crises, progressive renal failure, stroke, greater susceptibility to infections, splenic sequestration, and neurological development alterations (Ministry of Health, 2016; Brazil, 2025). Sickle cell anemia (homozygous beta-S globin mutation) is the most frequent and severe type. On the other hand, heterozygotes manifest only one mutated gene (HbAS) and are mostly asymptomatic. 4 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 Hemoglobin S combined with beta-thalassemia gives rise to S beta-thalassemia (Mota et al., 2024; Brazil, 2025). Performing the NST allows for early diagnosis, even before the appearance of symptoms, besides helping guide parents regarding preventive care for the newborn. When undiagnosed and untreated, patients may present with irritability, moderate fever, hemolytic anemia, hand-foot syndrome (dactylitis), infections, and splenomegaly (Ministry of Health, 2016). Another early-detected disease is phenylketonuria (PKU), which is an autosomal recessive inherited metabolic disorder resulting from mutations in the gene located on chromosome 12, leading to the deficiency or absence of the enzyme phenylalanine hydroxylase. This enzyme is essential for the metabolism of the amino acid phenylalanine (Phe), found in protein-rich foods. When not properly metabolized, phenylalanine accumulates in the blood, generating severe neurological lesions such as seizures, microcephaly, behavioral alterations, and growth disorders. It is one of the most common inborn errors of amino acid metabolism (Schwartz et al., 2023). This metabolic disorder leads to an increase in blood concentrations of phenylalanine (Phe) and its metabolites in body fluids and brain tissues, and greater urinary excretion of phenylpyruvic acid, a toxic metabolite. It can occur in forms such as classic phenylketonuria, where enzyme activity is less than 1%; mild phenylketonuria, where the enzyme has 1% to 3% activity; and transient or permanent hyperphenylalaninemia, where the enzyme activity level is greater than 3% (Ministry of Health, 2016). Children who do not receive treatment shortly after birth may present with seizures, impaired brain functions, neurological deficit, skin, dental, and ocular alterations, hyperactivity, global developmental delay, growth alteration, and a characteristic musty urine odor (Wyzykowski, 2022). The newborn screening test is performed by quantitative dosage of blood phenylalanine (Phe) in samples collected on filter paper; early diagnosis enabled by the test allows treatment to be carried out before the clinical picture develops (Ministry of Health, 2016). Biotinidase Deficiency (BTD) is another IEM identified by the NST. It is an autosomal recessive genetic disease caused by the inability to release and recycle biotin, an essential vitamin present in foods. This deficiency prevents the utilization of biotin bound to dietary proteins and leads to its loss through urine, compromising the activity of mitochondrial enzymes dependent on this vitamin (Ministry of Health, 2016). Clinical manifestations begin to appear around the seventh week of life with neuropsychomotor development delays, skin disorders, epileptic seizures, hypotonia, microcephaly, alopecia, and eczematoid dermatitis. When diagnosis is delayed, patients may present with sequelae such as motor and language delays, visual and auditory disorders, with potential irreversible sequelae or even risk of death (Wyzykowski, 2022). Early diagnoses with the newborn screening test are classified as suspected until diagnostic confirmation, which is performed with a quantitative test of biotinidase activity and can be reinforced with a genetic-molecular study. Treatment is simple and low-cost, carried out with daily doses of biotin (Ministry of Health, 2016). Congenital Hypothyroidism (CH) is caused by the malfunction of the newborn's thyroid gland in adequately producing thyroid hormones, resulting in a reduction of metabolic processes, and can be classified as primary when a failure of the thyroid gland occurs, secondary when pituitary TSH (thyroid-stimulating hormone) deficiency happens, and tertiary when the deficiency occurs in hypothalamic TRH (thyrotropin-releasing hormone) (Ministry of Health, 2016; Andrade et al., 2019). Because of the deficiency of thyroid hormones, which are important in the development of the Central Nervous System (CNS), malformation in CNS vascularization processes, synapse formation, neural migration, myelination, cell differentiation, dendritic arborization, and gene expression can occur (Wyzykowski, 2022). When diagnosis and treatment are not performed early, children may have their growth and mental development compromised, and clinical manifestations include muscular hypotonia, respiratory difficulties, cyanosis, prolonged jaundice, constipation, bradycardia, anemia, excessive drowsiness, livedo reticularis, hoarse cry, umbilical hernia, widened fontanelles, myxedema, heart murmur, feeding difficulty with deficient weightheight growth, teething delay, delayed bone maturation, dry and inelastic skin, neuropsychomotor development delay, and mental 5 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 retardation (Ministry of Health, 2016). The newborn screening test, from blood collection to the analysis of results, must occur quickly and without errors, and the initiation of treatment should take place in the first 14 days of life after collection, improving the newborn's quality of life (Wyzykowski, 2022). Congenital Adrenal Hyperplasia (CAH) comprises a group of autosomal recessive syndromes that correspond to various enzymatic deficiencies in the production of glucocorticoids, mainly cortisol, leading to adrenal hyperplasia and increased androgen production (Brazil, 2025). Diagnosis is performed through the quantification of 17-hydroxyprogesterone (17-OHP); clinical manifestations will depend on the enzyme involved and the level of enzymatic deficiency and may present glucocorticoid deficiency, mineralocorticoid deficiency, excess androgens, or even androgen insufficiency (Ministry of Health, 2016). The classic salt-wasting form is the most common form of deficiency; in girls, it will cause virilization of the external genitalia due to excess androgens during intrauterine life, whereas in boys, the external genitalia will be normal. Manifestation occurs early with an adrenal crisis: volume depletion, dehydration, hypotension, hyponatremia, and hyperkalemia and, if untreated, can progress to death. The classic non-salt-wasting form (simple virilizing) will show signs of virilization similar to the salt-wasting form, with females showing external genitalia virilization and males being identified late by signs of hyperandrogenism (increased growth velocity, early pubarche, or accelerated bone maturation). The non-classic (late-onset) form has a higher frequency than the classic form, and symptoms may appear in childhood or adolescence. In females, symptoms present with a slight enlargement of the clitoris, early pubarche, irregular menstrual cycles, hirsutism, and infertility, while in males, it is usually asymptomatic (Brazil, 2025). Early diagnosis and treatment performed with the newborn screening test can improve growth, which can be normalized in most cases (Ministry of Health, 2016). Cystic Fibrosis (CF) is an autosomal recessive genetic disease that causes a mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, which encodes the protein that transports substrates across membranes. These mutations are divided into six classes depending on the type of mutation they cause in the CFTR protein, whether it has higher or lower expression, or what alteration it will cause in epithelial cell functions (Procianoy et al., 2023; Brazil, 2025). Many newborns will not present symptoms during the first weeks, months, or even years. Due to the severity of the disease, early diagnosis performed with the newborn screening test is essential so that patients are treated before symptoms appear. The test is performed by analyzing immunoreactive trypsinogen (IRT) levels and should be carried out within a maximum of 30 days of life (Ministry of Health, 2016; Godoy et al., 2024). In May 2021, a significant legislative advance occurred with the sanction of Law No. 14.154, which expanded the NST offered by the SUS (Unified Health System). In the context of the SUS, newborn screening manages to track six diseases, which were described in the topics above. With the new law, the objective is for the exam to detect about 50 diseases, covering 14 distinct groups (Souza et al., 2025). This expansion represents a significant advance for public health in Brazil by enabling the early diagnosis and treatment of a substantially larger number of health conditions that, if not identified and treated in time, can lead to severe sequelae and even death (Ministry of Health, 2016). The Law provides that the expansion of the NST be implemented progressively, divided into five stages (Brazil, 2021). 6 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 Table 1 – Stages of the Newborn Screening expansion. 1st Stage - Diseases associated with excess phenylalanine (e.g., Phenylketonuria) - Congenital toxoplasmosis - Hemoglobinopathies (e.g., Sickle cell anemia, Thalassemias) 2nd Stage - Urea cycle disorders - Elevated blood galactose levels (Galactosemia) - Aminoacidopathies - Fatty acid beta-oxidation disorders 3rd Stage - Lysosomal storage diseases (affecting cellular functioning) 4th Stage - Primary Immunodeficiencies (genetic problems in the immune system) 5th Stage -Spinal Muscular Atrophy (SMA) Source: Authors' own elaboration (2025). 3.2 Care Required by Professionals When Performing the Newborn Screening Test The findings of this study and the literature show that the proper collection of the Newborn Screening Test requires compliance with specific steps that guarantee sample quality and, consequently, the reliability of the results. Collection should preferably be carried out between the 2nd and 5th day of life, and can be extended up to 30 days only in exceptional situations, given that delays can compromise the timely start of treatment (Wyzykowski, 2022). The correct procedure requires positioning the newborn comfortably, with the heel below heart level to promote blood circulation; sanitizing the area with 70% alcohol; performing light massage to stimulate flow; and puncturing the lateral regions of the plantar surface of the heel as guided by the Technical Manual of Newborn Screening (Ministry of Health, 2016). The first drop of blood must be discarded, and the filter paper must be filled homogeneously, ensuring that the blood uniformly saturates through the card (Brazil, 2018). Verifying sample quality must be done against the light, ensuring that all circles are completely impregnated. Figure 2 correctly demonstrates the appropriate puncture sites. Collection quality constitutes one of the fundamental pillars for the effectiveness of the NST, given that the accuracy of the results directly depends on obtaining appropriate samples. A well-executed collection ensures that the metabolic, genetic, and endocrine markers present in the newborn's blood are representative of the clinical condition, allowing diagnosis to occur within the appropriate period. This practice will enable the early diagnosis of metabolic, genetic, and endocrine diseases, allowing rapid interventions that can prevent severe sequelae and even the death of the newborn. Corroborating this perspective, Grosse et al. (2023) reinforce that sample quality is decisive for the reliability of newborn screening. Incomplete samples, poorly filled cards, excess blood, clotted samples, or those collected outside the recommended period are directly associated with false-negative or inconclusive results, besides increasing the need for recollection. This represents not only a clinical risk to the newborn, due to the possibility of delayed treatment, but also an operational impact on the health service, which needs to mobilize additional resources to repeat procedures. Despite the advances achieved by the program in recent years, and the existence of standardized operational protocols in primary care, some structural and operational challenges still compromise the efficiency of the newborn screening process. Infrastructure limitations in many basic health units, especially in more remote regions, still lack equipment, special collection rooms, or systems for registering and shipping samples; this hinders the standardization of procedures and can generate delays in the collection and transport of samples. 7 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 Figure 2 – Correct heel puncture site for newborn screening. Source: Brazil. Ministry of Health. Technical Manual: Biological Newborn Screening. 2nd ed. Brasília: Ministry of Health, 2021. The lack of training for professionals on the correct procedures for collecting heel blood, as this process requires specific technique and care regarding asepsis, volume, and storage. The absence of regular technique updates and training can result in inadequate, insufficient, or contaminated collections, and the need for recollection can delay diagnosis. Furthermore, an insufficiently trained professional may not adequately guide parents regarding the ideal timeframe for collection, reducing adherence within the proper period. According to the findings of Moura et al. (2022), even with advancements in the PNTN, difficulties among professionals in newborn care are visible, resulting in inadequate care and late attendance, since it is these professionals who accompany mothers from prenatal care onward, holding the important role of introducing mothers and family members to the benefits of the NST and the correct timeframe for performing the collection. Rodrigues et al. (2020) state that the lack of structured training for healthcare professionals is one of the main factors associated with technical errors in NST collection, such as inadequate filter paper filling, punctures in incorrect sites, and insufficient blood volume. The authors also highlight that inadequate collections significantly increase the number of rejected samples, generating the need for recollection and delaying early diagnosis. The lack of educational campaigns and effective communication with families remains an important obstacle. In various communities, especially in rural and peripheral areas, knowledge about the NST is limited, and many families do not understand its relevance, which leads to delays in performing the test or even a complete lack of collection. Mothers' attendance to have the NST performed is a crucial point, and according to studies by Moura et al. (2022), a large number of mothers do not attend within the 5-day timeframe, most often reporting this to be due to postpartum difficulties. Another barrier for professionals is the quality of the material provided for blood collection, which can cause the need for multiple punctures on the newborn's foot to obtain the adequate amount of blood. Table 2 – Main findings related to the Newborn Screening Test and references used. Finding Description Reference Quality of collection as a determining factor The effectiveness of the Newborn Screening Test depends on obtaining adequate samples, capable of correctly representing the clinical condition of the newborn and allowing early diagnosis. Grosse et al. (2023) Impact of inadequate samples Incomplete, clotted, excessive, or improperly timed samples can generate false-negative or inconclusive results and create the need for recollection. Grosse et al. (2023) 8 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 Structural limitations of services Infrastructure deficiencies, lack of adequate rooms, equipment, and registration and transport systems compromise standardization and delay the newborn screening process. Brazil (2016); Brazil (2021) Insufficient professional training The absence of continuous training and technical updating fosters collection errors, improper storage, and difficulties in newborn care. Moura et al. (2022) Technical errors in collection Puncturing in inappropriate sites, incorrect filling of the filter paper, and insufficient blood volume increase sample rejection and delay diagnosis. Rodrigues et al. (2020) Fragility in guidance to families Under-trained professionals may fail to provide proper guidance regarding the importance of the test and the ideal timeframe for its performance. Moura et al. (2022) Deficit of educational campaigns Families' limited knowledge about the Newborn Screening Test reduces adherence and favors delays or the absence of collection, especially in vulnerable regions. Alves, Santos, and Oliveira (2021); Araia et al. (2012) Maternal difficulties in the postpartum period Many mothers fail to show up within the recommended timeframe due to the difficulties experienced during the postpartum period. Moura et al. (2022) Problems related to collection material Inadequate materials can hinder sample acquisition and lead to multiple punctures on the newborn. Moura et al. (2022); Brazil (2018) Source: Prepared by the authors, based on Grosse et al. (2023), Moura et al. (2022), Rodrigues et al. (2020), Alves, Santos, and Oliveira (2021), Araia et al. (2012), and Brazil (2016; 2018; 2021). Insufficient guidance for postpartum women regarding the ideal timeframe for the NBS is also among the main reasons for delays in performing the test. A study by Alves et al. (2021) identified that mothers who did not receive clear explanations during prenatal care were up to three times more likely to have the test performed after the recommended deadline. In the chart shown in Figure 3, produced using data provided by the Ministry of Health, we can observe that the number of collection points registered under the NTSP between 2021 and 2024 reflects the capacity of the neonatal screening network in each Federal Unit (UF). It is observed that states such as Bahia (BA), Minas Gerais (MG), and Paraná (PR) have many collection points, which favors family access and program coverage. Conversely, states like Acre (AC), Amazonas (AM), Amapá (AP), and Roraima (RR) show low numbers of collection points, which may reflect structural and geographic limitations that restrict the reach of screening. Despite the gradual increase in the number of collection points in several states during the analyzed period, this expansion does not always translate into an effective improvement in collection quality; in some locations, the opening of new points is not accompanied by the training of professionals or the adequate supply of materials and inputs. Therefore, to ensure the effectiveness of the NTSP, it is essential to strengthen the neonatal screening network in an integrated manner, ensuring not only the expansion of collection points but also the quality of samples and the training of health teams performing the collections. This structural problem is reinforced by historical data: reports from the Ministry of Health in 2014–2016 already pointed to the need to expand the capillarity of the collection network to allow easy population access and continuous training for professionals to maintain collection quality (Ministry of Health, 2021). Operational and structural barriers gain even more relevance when considering that states with lower post density or geographical difficulties (such as the states in the Amazon region) already face lower coverage or lower frequencies of timely collections. A survey by the Chamber of Deputies indicated that in some states, collection within the first seven days of life can reach only 24%, while in others it exceeds 80%. This type of inequality compromises the early detection of severe diseases, given that the timing of neonatal collection is fundamental for effective screening (Brazil, 2023). 9 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 Figure 3 – Number of collection points registered under the National Newborn Screening Program (NTSP), reported by the Federal Units (UF), 2021–2024, Brazil. Legend: The chart presents the number of collection points registered under the National Newborn Screening Program (NTSP) in each federal unit of Brazil from 2021 to 2024. 3.3 Challenges Faced in Performing the Newborn Screening Test The challenges faced in properly performing the Newborn Screening (NBS) test in Brazil involve both structural limitations within health services and factors related to family adherence. One of the main obstacles identified in the literature is the lack of knowledge among mothers and family members regarding the purpose, importance, and ideal timeframe for collection, as noted by Mendes et al. (2017). They demonstrated that even when mothers knew about the right to the test, many were unaware of the screened diseases, the risk of sequelae, and the necessity of early diagnosis. This lack of information can negatively impact test adherence, reducing the likelihood of early detection and delaying the initiation of treatment before symptoms appear, which directly compromises children's prognoses. The analysis of data concerning family adherence to collection within the recommended timeframe (by the 5th day of life) between 2021 and 2024 reveals significant variations among the Federal Units (FUs). These indicators are essential for assessing not only family behavior but also the efficiency of primary care networks in complying with national newborn screening guidelines. Late collection can delay the start of treatment, reducing the positive impact of public policy; therefore, this data serves as a marker for both access and quality of care. According to the chart below (Figure 4), it is observed that states such as Amapá (AP), Paraná (PR), São Paulo (SP), and the Federal District (DF) present the highest percentages in certain years, reaching over 80% of collections performed within the ideal timeframe. On the other hand, units such as Pará (PA), Paraíba (PB), Pernambuco (PE), and Piauí (PI) record the lowest percentages, highlighting logistical challenges or difficulties in accessing collection points. These regional inequalities are also observed in studies by De Souza et al. (2025), who highlight that although national NBS coverage is broad, collection within the ideal period still varies expressively across states, especially in more vulnerable regions. This scenario reveals historical inequalities associated with infrastructure, logistics, and the availability of trained professionals, which directly impact the quality of neonatal screening. Out-of-window collection does not merely represent a failure of adherence, but also the inability of services to ensure adequate conditions for universal and timely access. Overall, a trend of gradual improvement is observed over the years, likely reflecting public policies such as awareness campaigns on the importance of newborn screening and expansion efforts in the number of collection points, as evidenced in the 10 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 previous chart. These advancements have contributed to reducing barriers to access, especially in interior regions, where the distance between the home and the basic health unit is frequently a limiting factor. Collection by the 5th day of life is essential for accurate diagnosis and early treatment initiation, before the appearance of symptoms, preventing severe sequelae and promoting a better quality of life for the newborn. Therefore, this family adherence reflects not only social engagement but also the effectiveness of public neonatal health policies. Figure 4 – Percentage of newborn screening test collections performed by the 5th day of life of the newborn, reported by the Federal Units (UF), from 2021 to 2024, Brazil. Legend: The chart presents the percentage of newborn screening test collections performed by the 5th day of life of the newborn in each federal unit of Brazil from 2021 to 2024. 3.4 Possible Impacts of the Absence or Delay in Performing the Newborn Screening Test The vast majority of disorders detected by the NBS present no symptoms in the first hours after birth, carrying a high risk of severe and irreversible sequelae in the child's development (Mendes et al., 2017). Neonatal screening programs only achieve their true impact when analyzed from a long-term perspective. Early diagnosis prevents permanent damage and substantially reduces the costs associated with late treatment of severe conditions. Conversely, the absence of early identification entails high lifetime medical costs, especially in metabolic and endocrine diseases. Late treatment tends to involve more intensive interventions, severe acute episodes, and the continuous need for long-term care, representing an increased financial and emotional burden on families—who end up dedicating a large portion of their time and income to the child's care—while also considerably elevating costs for the health system (Grosse et al., 2016). The absence of evident clinical signs of congenital hypothyroidism (CH) in the first days of life represents one of the major challenges for its diagnosis. According to Ford and LaFranchi (2014), this lack of initial manifestations stems from both the presence of some residual thyroid function in the newborn and the transplacental transfer of maternal thyroid hormones, which exerts a temporary protective effect. Although this physiological mechanism provides a window of metabolic stability, it also contributes to keeping CH clinically silent during the first weeks. This asymptomatic character reinforces the importance of neonatal screening, because in the absence of the test, diagnosis tends to occur only when the effects of hormonal deficiency are already established. Among the most frequent symptoms are compromised linear growth and, above all, impairments in neurological development, considering that thyroid hormones are essential for myelination and brain maturation. Thus, late diagnosis limits the effectiveness of therapeutic interventions and increases the risk of irreversible sequelae, making neonatal 11 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 screening an indispensable tool to guarantee a favorable prognosis, especially in diseases whose initial clinical presentation is subtle or absent, as in this case. Phenylketonuria (PKU) similarly causes severe neurological damage when not identified early. As described by Rovelli and Longo (2023), the deficiency in phenylalanine hydroxylase activity leads to systemic accumulation of phenylalanine, which crosses the blood-brain barrier and deposits in brain tissue. This accumulation directly interferes with metabolic pathways essential for neural development, including the synthesis of neurotransmitters such as dopamine, serotonin, and norepinephrine. If left untreated, the cerebral toxicity of phenylalanine results in severe manifestations, such as intellectual delay, microcephaly, epilepsy, behavioral disorders, hyperactivity, and global developmental impairment. Early intervention, primarily through a phenylalanine-restricted diet, is capable of almost entirely preventing such complications. Sickle cell disease (SCD) is recognized as one of the most prevalent genetic alterations in the world and represents a major public health problem, especially in countries with high population miscegenation. According to Boulet et al. (2010), the absence of early diagnosis and treatment significantly worsens the clinical course of the disease, preventing essential interventions to prevent painful crises, severe infections, and intense anemia. Without proper follow-up, the child becomes more vulnerable to septicemia, acute chest syndrome, strokes, and progressive organ damage, which can appear as early as the first years of life. The absence of early diagnosis in cystic fibrosis (CF) represents a major factor in the worsening of the disease. Without identification in the first months of life, recurrent respiratory infections can be misinterpreted as common childhood conditions, delaying the initiation of respiratory therapies, specific antibiotics, and nutritional supplementation. This contributes to irreversible lung damage, severe malnutrition, and growth impairment. Furthermore, manifestations such as pancreatic insufficiency, chronic diarrhea, and malabsorption may remain without proper management, leading to vitamin deficiencies, weight loss, and greater vulnerability to infections. A lack of diagnosis also impacts multidisciplinary follow-up, which is fundamental for long-term disease management, resulting in higher morbidity, repeated hospitalizations, and a significant reduction in both the quality and life expectancy (Okumura; Kleinhenz, 2016). Biotinidase deficiency (BTD) is a metabolic condition that, when left untreated, can lead to the rapid progression of neurological and cutaneous manifestations, many of which are irreversible. Without adequate biotin replacement, the child becomes susceptible to recurrent seizures, hypotonia, global developmental delay, sensorineural hearing loss, and motor coordination disorders such as ataxia. Failure to diagnose prevents the initiation of simple and highly effective therapeutic measures, increasing the risk of permanent sequelae and even fatal outcomes, despite being a treatable condition with an excellent prognosis when identified early (Tankeu et al., 2023). The lack of early diagnosis and treatment in congenital adrenal hyperplasia (CAH) can result in severe complications, especially in its classic forms. In the salt-wasting form, failure to recognize the condition rapidly leads to severe dehydration, hypotension, hyperkalemia, shock, and a high risk of neonatal death. Conversely, the virilizing form, when not identified at birth, can generate delays in managing genital ambiguity, psychosocial impacts, and difficulties in subsequent therapeutic decisions. Even the non-classic form, although milder, when undiagnosed, can evolve with precocious pubarche, menstrual disorders, infertility, and persistent hyperandrogenism (Silva; Kinoshita; Skraba, 2010). 12 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 Table 3 – Main diseases detectable by newborn screening, possible sequelae, and references used. Disease Sequelae/complications in the absence of early diagnosis Reference Congenital Hypothyroidism (CH) Linear growth deficit, neuropsychomotor development delay, impairment of cerebral myelination, and irreversible neurological sequelae. Ford & LaFranchi (2014) Phenylketonuria (PKU) Intellectual delay, microcephaly, epilepsy, behavioral disorders, hyperactivity, and global developmental impairment. Rovelli & Longo (2023) Sickle Cell Disease (SCD) Painful crises, septicemia, acute chest syndrome, stroke, severe anemia, and progressive organ damage. Boulet et al. (2010) Cystic Fibrosis (CF) Irreversible lung damage, recurrent respiratory infections, malnutrition, pancreatic insufficiency, malabsorption, and reduced life expectancy. Okumura & Kleinhenz (2016) Biotinidase Deficiency (BTD) Seizures, hypotonia, developmental delay, sensorineural hearing loss, ataxia, and risk of permanent sequelae or death. Tankeu et al. (2023) Congenital (CAH) Severe dehydration, shock, hyperkalemia, risk of neonatal death, unmanaged genital ambiguity, infertility, and hyperandrogenism. Silva, Kinoshita, & Skraba (2010) Adrenal Hyperplasia Source: Elaborated by the authors, based on the references cited in the manuscript. In addition to clinical and social hardships for families, the late diagnosis of conditions detected by the Newborn Screening (NBS) test imposes a substantial financial burden on the public healthcare system. Conditions such as congenital hypothyroidism, PKU, cystic fibrosis, and sickle cell disease, when left unidentified early, progress into severe complications that require frequent hospitalizations, highly complex interventions, prolonged therapies, and continuous multidisciplinary follow-up. These expenses far exceed the investment required for neonatal screening and early treatment, which are relatively straightforward and inexpensive. International economic studies demonstrate that every dollar invested in newborn screening programs can save five to ten dollars in future medical expenses—primarily by preventing hospitalizations, permanent sequelae, and intensive treatments (Grosse et al., 2016). Within the Brazilian context, this translates to heightened pressure on Unified Health System (SUS) resources, increased demand for specialized services, and expanded indirect costs associated with lifelong disability and lost productivity. Therefore, performing the NBS test within the ideal timeframe is paramount. The third chart (Figure 5) illustrates the PNTN percentage between 2021 and 2024, highlighting the program's reach across different Brazilian states. Although coverage in most states exceeds 80%, regional inequalities remain visible. The absence or delay of the NBS test can trigger severe consequences. Clinically, late diagnosis increases the risk of metabolic, neurological, and endocrine complications and sequelae. Furthermore, it creates a social and economic impact marked by escalating expenses for delayed treatments and heavier family burdens. In states where coverage and adherence percentages are lower, contributing factors often include inadequate laboratory infrastructure to perform tests, difficulties in sample transportation, a scarcity of trained professionals, and low public awareness regarding the importance of the NBS test. This analysis covering 2021 to 2024 suggests that despite gradual advancements in national coverage over recent years, optimizing neonatal screening still requires concerted governmental and managerial efforts, enhanced integration across healthcare networks, and targeted educational strategies for families. 13 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 Figure 5 – Percentage coverage of the NTSP, reported by the Federal Units (UF), 2021 to 2024, Brazil. Figure Legend: The chart illustrates the percentage coverage of the National Neonatal Screening Program (PNTN) across each federal unit in Brazil from 2021 to 2024. 3.5 Strategies to Optimize Information and Ensure the Proper Execution of Neonatal Screening Optimizing information and ensuring the proper execution of newborn screening require integrated strategies that involve educational actions for families, strengthened professional training, and the organization of care workflows. One of the main challenges identified is the timing of when information about the Newborn Screening (NBS) test is passed on to families. Although professionals and parents recognize that the postpartum period is not the most suitable time for educational interventions, many prenatal care workers still report insecurity or lack of preparation to guide pregnant women on the importance of screening (Araia et al., 2012). Thus, introducing health education starting in the prenatal period—using standardized materials, accessible language, and digital resources—can help increase parents' understanding of the test's importance and reduce compliance failures; effective education helps mitigate the psychosocial harms resulting from a lack of information. At the same time, the continuous training of the teams responsible for collection and family guidance is a fundamental step to guarantee the quality of the process. Periodic training, standardized protocols, and the use of checklists improve sample quality and reduce pre-analytical errors. Each collection unit must have at least two properly trained professionals for collection, who may be a nurse, nursing technician, or nursing assistant (Oliveira & Souza, 2017). Another essential component is strengthening the communication of results, using sensitive approaches and materials designed for families, which reduces anxiety and favors proper follow-up. As guided by the Ministry of Health (2002), normal results should be communicated to those responsible as early as possible, whereas altered results require immediate contact, clear guidance, and a request for a new collection for diagnostic confirmation. This promptness is decisive for initiating early interventions and preventing irreversible sequelae. Educational actions, organized workflows, and structured communication are fundamental to enhancing the effectiveness of neonatal screening programs across different realities; a traceability system, combined with consolidated public policies, reinforces network efficiency and enables early, equitable interventions. Certain tested strategies have demonstrated efficacy in optimizing newborn screening, reinforcing the need for integrated educational and organizational intervention. A randomized controlled trial in the United States showed that prenatal 14 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 education about the newborn screening test, using multimedia tools and electronic platforms, significantly increased maternal postpartum knowledge and screening acceptance without negatively impacting test compliance (Botkin et al., 2016). In Brazil, studies with postpartum women reveal a limited understanding of the ideal collection timeframe and the benefits of the test, highlighting the importance of including guidance during prenatal care rather than only at hospital discharge (Santos et al., 2011). The articulation between child health care programs and neonatal screening services also proves effective: a study in São Paulo identified that workflow organization strategies among maternity hospitals, collection posts, and laboratories can improve early access to the exam (Carvalho et al., 2020). Finally, the Technical Manual of the National Neonatal Screening Program of the Ministry of Health also recommends the systematic training of health professionals and early guidance for pregnant women during prenatal care as an integral part of an equitable, quality screening network. Integrating the results with theoretical evidence makes it clear that the PNTN, despite being nationally consolidated, still faces considerable challenges related to equity in access, family compliance, insufficient infrastructure, and the logistical management of the collection network. The presented charts clearly illustrate these disparities, providing empirical support to the points discussed in the review and showing that the full consolidation of neonatal screening in Brazil depends not only on network expansion, but on overcoming the structural and operational bottlenecks that persist across various regions of the country. 4. Conclusion The NBS is an essential tool for the early detection of genetic, metabolic, and endocrine disorders, enabling treatment and the prevention of severe and irreversible sequelae, reducing neonatal morbidity and mortality, and promoting a better quality of life for affected children. Within this context, the NTSP represents a highly relevant public policy in the field of child health, marking a milestone in health surveillance and the guarantee of fundamental rights in early childhood. However, despite major advancements achieved since its implementation, significant challenges still persist that compromise the program's full effectiveness—especially regional inequality in coverage, infrastructure deficiencies at certain collection points, flaws in sample transportation logistics, and a lack of adequate training among professionals involved in the process. Additionally, a lack of public information contributes to delays in test collection. Faced with this scenario, it is evident that overcoming these obstacles requires continuous and coordinated governmental efforts, with investments in the expansion and qualification of the screening network and the modernization of the infrastructure needed to guarantee the speed and reliability of results. The formulation of public policies that ensure equity in access and reduce regional disparities is also fundamental. Alongside this, the importance of comprehensive educational strategies aimed at health professionals, families, and communities is emphasized. Raising awareness of the value of the NBS in preventing severe sequelae, coupled with the proper training of teams responsible for collection and follow-up, is essential to ensure that the procedure is performed within the correct timeframe, with technical quality and an understanding of its impact on child health. Thus, it is concluded that the effectiveness of the NTSP depends on the integration of governmental, structural, and educational actions. Only through these efforts will it be possible to consolidate the NBS as a fully realized health promotion strategy, ensuring children have expanded opportunities for prevention and care. References Alves, J. B., et al. (2021). Maternal knowledge about newborn screening and factors associated with delayed collection. Revista Saúde em Debate, 45(131). Andrade, C., et al. (2019). Congenital hypothyroidism as a risk factor for central auditory processing disorders. Revista Paulista de Pediatria, 37(1). 15 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 Araia, M. H., et al. (2012). Factors associated with knowledge and satisfaction with newborn screening education: A survey of mothers. Genetics in Medicine, 14(12), 963–970. https://doi.org/10.1038/gim.2012.87 Bhattacharya, K., Wotton, T., & Wiley, V. (2021). The evolution of blood-spot newborn screening. International Journal of Neonatal Screening, 7(1), 63–70. Botkin, J. R., et al. (2016). Prenatal education of parents about newborn screening and residual dried blood spots: A randomized clinical trial. JAMA Pediatrics, 170(6), 543–549. https://doi.org/10.1001/jamapediatrics.2015.4850 Boulet, S. L., Yanni, E. S., Creary, M. S., & Olney, R. S. (2010). Health status and healthcare use in a national sample of children with sickle cell disease. American Journal of Preventive Medicine, 38(4 Suppl), S528–S535. Brazil. Chamber of Deputies. (2023). Newborn screening coverage is highly uneven across Brazilian states, https://www.camara.leg.br/noticias/992769-cobertura-do-teste-do-pezinho-e-muito-desigual-no-estados-brasileiros-aponta-levantamento/ survey shows. Brazil. Ministry of Health. (2001). Ordinance No. 822, of June 6, 2001. Establishes, within the scope of the Unified Health System, the National Neonatal Screening Program – NTSP. Brazil. Ministry of Health. (2002). Manual of technical standards and operational routines for the National Neonatal Screening Program. Brasília, DF. Brazil. Ministry of Health. (2016). Biological newborn screening: Technical manual. Brasília, DF. Brazil. Ministry of Health. (2018). What is the proper technique to perform the newborn screening test? https://aps-repo.bvs.br/aps/qual-a-tecnica-adequada-para-realizar-o-teste-do-pezinho/ Brazil. Ministry of Health. (2021). Information booklet: Newborn screening – 2014–2016 data. Brasília, DF. Brazil. Ministry of Health. (2021). Technical manual: Biological Newborn Screening (2nd ed.). Brasília, DF. Brazil. Ministry of Health. (2021). Newborn screening test will be expanded and will detect up to 50 new diseases. https://www.gov.br/pt-br/noticias/saude-e-vigilancia-sanitaria/2021/05/teste-do-pezinho-sera-ampliado-e-detectara-ate-50-novas-doencas Brazil. Ministry of Health. (2024). Ministry develops actions to restructure the National Neonatal Screening Program. https://www.gov.br/saude/pt-br/assuntos/noticias/2024/junho/ministerio-desenvolve-acoes-para-reestruturar-o-programa-nacional-de-triagem-neonatal Brazil. Ministry of Health. (2025). Newborn Screening. https://www.gov.br/saude/pt-br/composicao/saes/triagem-neonatal Cossu, M., et al. (2023). Metabolomic studies in inborn errors of metabolism: Last years and future perspectives. Metabolites, 13(3), 447. https://doi.org/10.3390/metabo13030447 De Souza, C. F. M., Tonon, T., Silva, T. O., & Bachega, T. A. S. S. (2025). Newborn screening in Brazil: Realities and challenges. Journal of Community Genetics, 16(4), 431–438. Fernandes, J. M. B., Vieira, L. T., & Castelhano, M. V. C. (2023). Revisão narrativa enquanto metodologia científica significativa: reflexões técnico-formativas. REDES – Revista Educacional da Sucesso, 3(1), 1–7. ISSN: 2763-6704. Ford, G., & LaFranchi, S. H. (2014). Screening for congenital hypothyroidism: A worldwide view of strategies. Best Practice & Research Clinical Endocrinology & Metabolism, 28(2), 175–187. https://doi.org/10.1016/j.beem.2013.05.008 Godoy, C. (2024). Cystic fibrosis: When newborn screening is unsatisfactory for early diagnosis. Revista Brasileira de Saúde Materno Infantil, 24. Grosse, S. D., et al. (2023). Quality of dried blood spot samples and its impact on newborn screening performance. Molecular Genetics and Metabolism, 140. Grosse, S. D., Thompson, J. D., Ding, Y., & Glass, M. (2016). The use of economic evaluation to inform policy decisions about newborn screening: The Washington State experience. The Milbank Quarterly, 94(2), 366–391. https://doi.org/10.1111/1468-0009.12196 Jeanmonod, R., Asuka, E., & Jeanmonod, D. (2025). Inborn errors of metabolism. In StatPearls. StatPearls Publishing. Kern, I., Foland, P., & Ballhausen, D. (2023). Inborn errors of metabolism: A specialty at the forefront of precision medicine. Revue Médicale Suisse, 19(815), 358–361. https://doi.org/10.53738/REVMED.2023.19.815.358 Mendes, L. Q., et al. (2017). Parents’ knowledge regarding newborn screening: Contribution of the "Portal dos Bebês – Teste do Pezinho" website. Revista CEFAC, 19(4), 478–488. https://doi.org/10.1590/1982-021620171949616 Mota, C., et al. (2024). Àgô Sankofa: A look at the trajectory of sickle cell disease in Brazil over the last 20 years. Ciência & Saúde Coletiva, 29, e06772023. Moura, R. P., Silva, L. M., Queiroz, F. S., Rothebarth, A. P., Biork, R. N., & Mufalo, L. P. (2022). Newborn screening: Knowledge and difficulties of nursing professionals in Primary Health Care. Revista da Sociedade Brasileira de Enfermagem Pediátrica, 22, eSOBEP2022022. Ogassawara, D., et al. (2025). Trilhas metodológicas para a revisão narrativa: orientações pragmáticas para sua elaboração. Ensino & Pesquisa, 23(3). https://doi.org/10.33871/23594381.2025.23.3.10317 Okumura, M. J., & Kleinhenz, M. E. (2016). Cystic fibrosis transitions of care: Lessons learned and future directions for cystic fibrosis. Clinics in Chest Medicine, 37(1), 119–126. Oliveira, E. F., & Souza, A. P. (2017). The importance of early newborn screening: The nurse’s role in guiding neonatal screening. ID on line. Revista de Psicologia, 11(35), 361–378. https://doi.org/10.14295/idonline.v11i35.742 16 Research, Society and Development, v. 15, n. 9, e7415951725, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51725 Pereira, A. S., et al. (2018). Metodologia da pesquisa científica [Free ebook]. Editora da UFSM. Procianoy, E. A., Neto, N. L., & Ribeiro, A. F. (2023). Patient care in cystic fibrosis centers: Real-world analysis in Brazil. Jornal Brasileiro de Pneumologia, 49(1). Risemberg, R. I. C. et al. (2026a). A importância da metodologia científica no desenvolvimento de artigos científicos. E-Acadêmica, 7(1), e0171675. https://eacademica.org/eacademica/article/view/675 Risemberg, R. I. C., Wakin, M., & Shitsuka, R. (2026b). Qualitativa, quantitativa ou quali-quantitativa: Como identificar de modo rápido a abordagem de um artigo científico? E-Acadêmica, 7(2), e0172702. https://doi.org/10.52076/eacad-v7i2.702 Rodrigues, A. L., et al. (2020). Factors associated with newborn screening sample inadequacy. Revista Brasileira de Enfermagem, 73(6). Rovelli, V., & Longo, N. (2023). https://doi.org/10.1016/j.ymgme.2023.107583 Phenylketonuria and the brain. Molecular Genetics and Metabolism, 139(1), 107583. Santos, M. L. (2024). Comprehensive study on urea cycle disorders (UCDs) in Brazil [Master’s thesis, Federal University of Rio Grande do Sul]. Schwartz, I. V., et al. (2023). Neuropsychological and quality of life outcomes in PKU patients: Expert recommendations of assessment tools in Brazil. Arquivos de Neuro-Psiquiatria, 81(7). Silva, I. N., Kinoshita, E. M., & Skraba, C. M. (2010). Congenital adrenal hyperplasia: Diagnosis, treatment, and follow-up. Revista Paulista de Pediatria, 28(3), 364–371. Souza, C. F., et al. (2025). Newborn screening in Brazil: Realities and challenges. Journal of Community Genetics, 16(2), 1–12. Tang, C., et al. (2024). Newborn screening for inborn errors of metabolism by next-generation sequencing combined with tandem mass spectrometry. International Journal of Neonatal Screening, 10(2), 28. https://doi.org/10.3390/ijns10020028 Tankeu, A. T., et al. (2023). Biotinidase deficiency: What have we learned in forty years? Molecular Genetics and Metabolism, 138(4), 107560. https://doi.org/10.1016/j.ymgme.2023.107560 Wyzykowski, C. (2022). Newborn screening in the state of RS https://revistasaudecoletiva.com.br/index.php/saudecoletiva/article/view/2190 17 and its quality indicators. Saúde Coletiva, 12(2), 961–972.